

PRESS RELEASE

NTC and Sightsavers Italia ETS, partners to promote eye health

With the aim of contributing to projects that promote the importance of vision and the prevention and treatment of eye diseases, NTC has embraced the support of Sightsavers Italia ETS.

Milan, July 8th 2024 - The World Health Organisation (WHO) notes that at least 2.2 billion people in the world have a vision impairment. In addition, at least one billion of these are affected by avoidable visual impairment that could have been prevented or is yet to be addressed, such as cataract in which early diagnosis play a key role in reducing visual impairment and an operation can restore sight.

Cataracts can be present from birth or develop because of injury to the eye or be age-related or might also happen after eye surgery caused by other diseases.

"Cataract remains the largest cause of blindness worldwide and, especially in children suffering from this disease, it is necessary to intervene in time to avoid compromising the development of sight and the risk of blindness," says Alessandro Colombo, Chief Scientific Officer of NTC, "Our commitment to support Sightsavers is in line with our vocation to contribute to the prevention and treatment of eye diseases worldwide".

In response to this situation, and in continuity with its commitment to raise awareness on the prevention and treatment of eye diseases, NTC has chosen to support Sightsavers Italia ETS, which works in some of the poorest areas of the world to protect sight, prevent avoidable blindness and fight for the rights of people with disabilities (www.sightsavers.it). 17 million people are blind due to cataract: 465,658 cataract operations were performed by Sightsavers in 2023.

About NTC

NTC is a pharmaceutical company headquartered in Milan - Italy, with distributors and partners in over 100 countries in the world, engaged in research, development, registration and commercialization of drugs, medical devices, and food supplements in ophthalmology, but also in other therapeutic areas like gastro-metabolism, gynecology, and pediatrics. NTC offers to its partners, currently nearly 250 companies, innovative pharmaceutical products with high quality standards. For more information, please visit www.ntcpharma.com

ntc S.r.l.

Sede legale
via Luigi Razza, 3
20124 Milano
Italia

Sede operativa
Via dei Gracchi, 35
20146 Milano
Italia

Unità locale
Via Dei Gracchi, 26
20146 Milano
Italia

Tel. +39 02 438 504 1
Fax +39 02 444 032 75

Pec: ntc@legalmail.it
E-mail: info@ntcpharma.com

REG. IMP. MI. / C.F. / P.IVA:
03503980967
R.E.A.:1680028
Capitale sociale € 8.000.000,00 i.v.